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INTRODUCTION:
Patients with early stage prostate cancer have excellent cause specific survival after definitive local therapy with radiation therapy or radical prostatectomy. However, regardless of race, men of lower socioeconomic status are less likely to receive definitive local therapy for early stage disease, and when such treatment is administered, they are more likely to die of their cancer. Men of lower socioeconomic status are also more likely to have treatment related complications after prostate cancer treatment. This suggests that disparities in treatment, rather than prostate cancer screening, may play a causative role in observed differences. We hypothesize that socioeconomic disparities in prostate cancer survival are associated with distinct differences in quality of care that can be identified and measured using standard medical diagnosis and treatment codes. Therefore, our aims are 1. to identify socioeconomic disparities in outcomes after treatment for localized prostate cancer, 2. to identify socioeconomic disparities in quality of care for localized prostate cancer and 3. To develop a tool to measure disparities in quality of care for localized prostate cancer.
BODY:
In this section of the report, I am to describe the research accomplishments associated with each task outlined in the approved Statement of Work. I have copied my approved statement of work below. As planned, I am currently in the data organization period of work, and do not as of yet have data analysis or results to present. As stated in Phase I, we have obtained IRB approvals as well as access to the SEER Medicare linked dataset. The IRB approval process took approximately 3 months. We sought access to SEER Medicare linked data concurrently. This took over 6 months to achieve due to staffing shortages at the NCI, and we have recently received the data. During this interval we also sought appropriate statistical support. With the help of grant funds, we are providing partial salary support to a recent PhD from our department of biostatistics and epidemiology, Clayton Schupp. On a personal note, I was on maternity leave from May to September, and had sought DOD approval for leave during this period.
STATEMENT OF WORK
As for Phase II of our statement of work, our first look at the dataset demonstrates that there will be a significant amount of work required to evaluate and clean the dataset for analysis. (Table 1) There are many cases for which variables are unknown that will need to be explored within the SEER dataset. In addition, significant programming will be required to score comorbidities, P rostate cancer exhibits the largest differences in incidence and survival among races and ethnicities of any cancer site. 1 Meta-analyses have shown an approximately 13% increased risk of prostate cancerspecific death in African Americans when compared with whites after adjusting for clinical predictors. 2 There are numerous theories about why the mortality rates are higher in minority groups, including differences in tumor aggressiveness and stage at diagnosis, treatment, socioeconomic factors, patient beliefs, and physician biases. 1 To date, the cause of the disparities in incidence and survival remain unknown.
Differences in the outcomes of men with prostate cancer also persist with regards to socioeconomic status (SES). In one large, community-based series, it was found that men age 65 years or older living in the lowest socioeconomic quartile were 31% more likely to die of local or regional-staged prostate cancer than those in the highest quartile. 3 This is at least partially attributed to the fact that SES, and income in particular, has been associated using watchful waiting rather than surgery or radiation in men with low-risk prostate cancer. 4 Although there is a large amount of literature concerning the relationships of race and socioeconomic status to prostate cancer-specific treatment and survival, the roles that these factors play in cancer-specific survival after treatment have not been addressed. Using a statewide database, we primarily sought to evaluate the impact of SES on the likelihood of undergoing radical prostatectomy (RP) and the ensuing effect on cancer-specific survival (CSS) after surgery for men with low-risk (Gleason Յ7) localized prostate cancer. Secondarily, we determined the impact of SES on the likelihood of undergoing external beam radiotherapy (XRT) and the ensuing effect on CSS after therapy for men with low-risk localized disease.
MATERIAL AND METHODS

Subjects and Databases
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All prostate cancer cases between 1996 and 2005 were identified. Patients were excluded if Gleason score on prostate biopsy was Ͼ7 or if disease was not clinically localized to the prostate at the time of diagnosis. The measure of SES used in this analysis was a composite measure previously created by Yost et al using CCR and census data. 6 Census files were linked to the CCR file based on the cases' block group of residence at the time of diagnosis. Cases that were not able to be geocoded to a street address (5.5% of cases) were randomly allocated to census blocks within their county of residence. Cases diagnosed from 1996 forward were linked to 2000 census data. Principal components analysis was then used to create a composite SES score using several census variables, including median household income, education level, proportion below 200% poverty level, and median house value. Quintiles of SES score were used in the analysis, with a value of 1 representing the lowest SES level and a value of 5 representing the highest SES level. Table 1 illustrates the demographic characteristics of the study population.
Variables
For each identified case, data regarding race, age, year of diagnosis, and treatment type were abstracted. All analyses used the American Joint Committee on Cancer (AJCC) TNM staging system related to time of diagnosis.
The CCR database classifies race as white, African American, Hispanic, Asian-Pacific Islander, or other; and treatment type as radical prostatectomy, other surgery, radiation, chemotherapy, hormone therapy, other therapy, or no therapy. We defined radical prostatectomy solely as radical prostatectomy with or without lymphadenectomy.
Statistical Analysis
Descriptive statistics were used to summarize the demographic characteristics of the study population. Bivariate analyses were conducted to examine the relationships between: (1) SES and radiation therapy and (2) SES and radical prostatectomy, stratified by the following variables: year of diagnosis, race, and age group. Mantel-Haenszel odds ratios and their 95% confidence intervals were generated. For the survival analyses, our outcome of interest was death resulting from prostate cancer; deaths from other causes were censored at the time of death. Cause of death was categorized according to the International Classification of Diseases system. Cases with ICD-9 cause of death code 185 and those with ICD-10 cause of death code C61 were designated as having died of prostate cancer. Unadjusted survival curves by SES were produced using the Kaplan-Meier method. Cox proportional hazards models were generated to examine the effect of SES on survival from prostate cancer. Two separate models were produced, one for patients who received radiation therapy and another for those who underwent radical prostatectomy. The models were adjusted for age and race/ethnicity. Log-log plots were used to test the proportionality assumption of the model. No violations of this assumption were found upon examination of these plots. SAS 9.1 software was used for all analyses (SAS Institute, Inc., Cary, NC).
RESULTS
Between January 1996 and December 2005, we identified 39,234 patients (31.7% of total) who underwent radical prostatectomy (RP) as initial therapy for clinically localized, Gleason Յ7 prostate cancer (Table 1) . Over the same time frame, we identified 42,431 men (34.2%) who underwent XRT as initial therapy for the same disease. Patients in the study ranged in age from 34-104 years (mean, 67 years), and median follow-up was 53 months (range, 0-119). Five-hundred seventy-three men (0.5%) died of prostate cancer in the radiation group, and 210 patients (0.2%) died of prostate cancer in the RP group. Median survival was 51 and 64 months in those who received RP and XRT, respectively.
Men of lower SES who underwent RP had a higher odds of cancer-specific death over the time frame studied (Table 2A ). In fact, men of the lowest socioeconomic status were 2.0 times more likely to die of prostate cancer than their counterparts in the highest SES after RP (95% CI 1.28-3.09, P ϭ .002). When adjusted for race, the differences were even more disparate as patients in the lowest SES were 2.20 times more likely to die of prostate cancer than the highest SES (95% CI 1.38-3.50, P ϭ .001). These results are displayed graphically in Fig. 1 .
Similarly, men of lower SES who underwent XRT had a significantly higher risk of prostate cancer-specific death ( Table 2B ). Men of the lowest socioeconomic status were 2.24 times more likely to die of prostate cancer than those in the highest SES after radiation (95% CI 1.71-2.94, P Ͻ.001). The differences were comparable when adjusted for race, with those of the lowest SES being 2.21 times more likely to die of prostate cancer (95% CI 1.66-2.95, P Ͻ.001). These results are displayed graphically in Fig. 2 . 59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116   59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115 116
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COMMENT Prostate cancer is a disease that exhibits profound racial and social disparities in regards to incidence, treatment, and outcome. 7 Prior studies have documented differences of approximately 13% in prostate cancer-specific survival, favoring whites over African Americans, although other studies have demonstrated that racial difference in survival was completely eliminated after further adjustment for tumor grade, socioeconomic status, and year of diagnosis. 7 We sought to examine the relationship between SES and treatment administered as well as prostate cancer-specific survival after definitive treatment (XRT or RP) in patients with low-risk prostate cancer.
Our results show that men of lower SES are half as likely to undergo radical prostatectomy for low-risk disease than those of higher SES. When adjusted for race, the difference was even more profound. This is despite the fact that men of lower SES have been found to be much more likely to be diagnosed with localized prostate cancer. 8 The reasoning behind this is likely multifactorial. Income level has been shown to be an independent predictor of prostatectomy, with lower income patients demonstrating a decreased likelihood of choosing surgery. 4 The disparity in treatment may be a result of patient-driven factors, such as work-related or financial stressors, and poor access to centers that offer prostatectomy. 9 This may also be due to physician factors, namely financial or other disincentives to offer prostatectomy to patients of lower SES. Finally, comorbidities may play a large factor in treatment selection, both for patients and physicians.
Racial disparities in surgical care have not been limited to prostate cancer. Studies have demonstrated that disparities exist in the treatment of esophageal and cervical cancers, with African Americans being less likely to undergo appropriate surgical intervention than their white counterparts. 10 This may be caused in part by health care access, but distrust in the health care system, and surgical intervention in particular, also likely plays a role. 11 Despite treatment choice, we also found that men of lower SES who underwent either RP or radiation treatment for low-risk prostate cancer were approximately twice as likely to die of prostate cancer than their higher SES counterparts. Although the absolute numbers of men dying of low-risk disease were low, the differences attributed to SES were significant. Patients generally do well after definitive local treatment for low-risk prostate cancer; however disease-free outcome has been linked to variations in technique. Studies have demonstrated that positive surgical margins, a quality-control indicator in prostatectomy, affect disease-free survival after surgery, even in low-risk disease. 12 Similarly, when it comes to definitive radiation therapy, administrative technique and dosimetry, both independent quality indicators, are known to predict biochemical failure and the likelihood of developing distant metastases. 13, 14 The differences with regards to cancer-specific survival among the higher and lower SES quartiles after definitive therapy may also be a result of clinical factors not detected in the CCR dataset. These variables include initial prostate-specific antigen and biopsy tumor burden, neither of which were incorporated into the dataset used. The slight survival differences may also be attributable to variations in the initial treatments or techniques available to patients of lower SES. Finally, another potential factor lies in the fact that men of higher SES may receive more thorough post-treatment surveillance than men of lower SES.
This study does have limitations. As previously mentioned, the CCR database does not include information on surgical margin status or dosimetry and technique of radiation administered-key components of disease-free survival. There is also no data regarding PSA status or initial tumor volume in the CCR dataset. Thus, some of the patients may not have truly been "low-risk" by strict criteria. Comorbidites are also not accounted for, because these may play into treatment choices and post-treatment outcomes. Finally, as with any large database analysis, there exists the possibility of data entry miscoding. This potential error, however, should be nonselective over the cohort analyzed, and in effect, cancel out any overt bias.
This study has demonstrated that, in the setting of low-risk disease, men of lower SES are less likely to have definitive local therapy. Moreover, men of lower SES have decreased disease-specific survival even when treated definitively for low-risk prostate cancer. These findings point to the need for improvement in prostate cancer screening and treatment for men of lower SES.
CONCLUSIONS
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